7,261 reports of this reaction
2.1% of all CETIRIZINE HYDROCHLORIDE ALLERGY reports
#4 most reported adverse reaction
ALOPECIA is the #4 most commonly reported adverse reaction for CETIRIZINE HYDROCHLORIDE ALLERGY, manufactured by Aurohealth LLC. There are 7,261 FDA adverse event reports linking CETIRIZINE HYDROCHLORIDE ALLERGY to ALOPECIA. This represents approximately 2.1% of all 341,924 adverse event reports for this drug.
Patients taking CETIRIZINE HYDROCHLORIDE ALLERGY who experience alopecia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ALOPECIA is a less commonly reported adverse event for CETIRIZINE HYDROCHLORIDE ALLERGY, but still significant enough to appear in the safety profile.
In addition to alopecia, the following adverse reactions have been reported for CETIRIZINE HYDROCHLORIDE ALLERGY:
The following drugs have also been linked to alopecia in FDA adverse event reports:
ALOPECIA has been reported as an adverse event in 7,261 FDA reports for CETIRIZINE HYDROCHLORIDE ALLERGY. This does not prove causation, but indicates an association observed in post-market surveillance data.
ALOPECIA accounts for approximately 2.1% of all adverse event reports for CETIRIZINE HYDROCHLORIDE ALLERGY, making it a notable side effect.
If you experience alopecia while taking CETIRIZINE HYDROCHLORIDE ALLERGY, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.